EP0352092A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel antibiotics R106
Assignee: Takara Shuzo Co Ltd
•
Filing: 1989-07-19
•
Granted: —
•
Expires: 2009-07-19
Abstract
Abstract Antibiotic compounds R106 of formula (I): are antifungal agents. They may be produced by culture of microorganisms of the genus Aureobasidium , e.g. of new species Aureobasidium pullulans No.R106 exemplified by the type strain deposited under accession No.FERM BP-1938.
Inventors
- 👤 Kazutoh Takesako
- 👤 Kazuo Shimanaka
- 👤 Junko Yamamoto
- 👤 Fumiyo Haruna
- 👤 Teruya Nakamura
- 👤 Hideyo Yamaguchi
- 👤 Katsuhisa Uchida
- 👤 Katsushige Ikai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 08:38
CPC Classifications
C; C07; C07K; C07K11/00; C07K11/02; C07K7/00; C07K7/02; C12; C12N; C12N1/00; C12N1/14; C12N1/145; C12P; C12P21/00; C12P21/02; A; A61; A61K; A61K38/00; C12R; C12R2001/00; C12R2001/645
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
60 words
An antibiotic R106 represented by general formula (I): wherein : MeVal is N-methylvaline; Phe is phenylalanine; Pro is proline; Leu is leucine; R is methyl or ethyl; X₁ is N-methylphenylalanine, β-hydroxy-N-methylphenylalanine, or phenylalanine ; X₂ is alloisoleucine, valine or leucine; X₃ is N-methylvaline or valine; and X₄ is β-hydroxy-N-methylvaline, α-hydroxy-N-methylvaline, N-methylvaline, valine, N, β-dimethylaspartic acid, β-hydroxy-N-methylphenylalanine, β-methylphenylalanine, N-methyl-2,3-didehydrovaline, or N-methyl-3,4-didehydrovaline.
Claim 2
Dependent Claim
60 words
An antibiotic R106 represented by general formula (I): wherein : MeVal is N-methylvaline; Phe is phenylalanine; Pro is proline; Leu is leucine; R is methyl or ethyl; X₁ is N-methylphenylalanine, β-hydroxy-N-methylphenylalanine, or phenylalanine ; X₂ is alloisoleucine, valine or leucine; X₃ is N-methylvaline or valine; and X₄ is β-hydroxy-N-methylvaline, α-hydroxy-N-methylvaline, N-methylvaline, valine, N, β-dimethylaspartic acid, β-hydroxy-N-methylphenylalanine, β-methylphenylalanine, N-methyl-2,3-didehydrovaline, or N-methyl-3,4-didehydrovaline.
Claim 3
Dependent Claim
29 words
A process for producing antibiotic R106 according to claim 1 which comprises culturing an R106 antibiotic-producing microorganism of the genus Aureobasidium and collecting said antibiotic from the fermentation broth.
Claim 4
Dependent Claim
26 words
A process according to claim 2 wherein said microorganism is of the species Aureobasidium pullulans No.R106 exemplified by the type strain deposited under accession No.FERM BP-1938.
Claim 5
Dependent Claim
23 words
A process according to claim 3 wherein the microorganism is that deposited under the accession No.FERM BP-1938, or a derivation or mutant thereof.
Claim 6
Dependent Claim
16 words
Microorganisms of the species Aureobasidium pullulans No.R106 exemplified by the strain deposited under accession No.FERM BP-1938.
Claim 7
Dependent Claim
16 words
Microorganisms of the species Aureobasidium pullulans No.R106 exemplified by the strain deposited under accession No.FERM BP-1938.
Claim 8
Dependent Claim
17 words
Microorganisms of the type strain deposited under accession No.FERM BP-1938 and R106 antibiotic-producing derivatives and mutants thereof.
Claim 9
Dependent Claim
17 words
Microorganisms of the type strain deposited under accession No.FERM BP-1938 and R106 antibiotic-producing derivatives and mutants thereof.
Claim 10
Dependent Claim
14 words
Microorganisms of the genus Aureobasidium capable of producing R106 antibiotic according to claim 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.